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Abstract
Currently, one of the main challenges in human molecular genetics is the interpretation of rare genetic variants of unknown
clinical significance. A conclusive diagnosis is of importance for the patient to obtain certainty about the cause of the disease, for
the clinician to be able to provide optimal care to the patient and to predict the disease course, and for the clinical geneticist for
genetic counseling of the patient and family members. Conclusive evidence for pathogenicity of genetic variants is therefore
crucial. This review gives an introduction to the problem of the interpretation of genetic variants of unknown clinical significance
in view of the recent advances in genetic screening, and gives an overview of the possibilities for functional tests that can be
performed to answer questions about the function of genes and the functional consequences of genetic variants (Bfunctional
genomics^) in the field of inborn errors of metabolism (IEM), including several examples of functional genomics studies of
mitochondrial disorders and several other IEM.
Whole exome and whole genome sequencing
The introduction of next generation sequencing, and in par-
ticular of whole exome sequencing (WES), as a tool in a
routine molecular genetics diagnostics setting, has revolu-
tionized the field of molecular genetics and IEM. In the pre-
NGS era, often a large number of functional diagnostic
tests, such as metabolite screening and enzyme analysis,
were needed to establish a biochemical diagnosis and to
identify candidate genes, which were subsequently se-
quenced one by one. Nowadays, WES is used routinely as
a tool to diagnose many different IEMs. WES is particularly
suitable to diagnose disorders with a large number of can-
didate genes and a broad clinical spectrum, such as mito-
chondrial disorders or congenital disorders of glycosylation
(Timal et al. 2012; Wortmann et al. 2015, 2015). In addi-
tion, both the cost-effectiveness and quality of the sequence
data have increased tremendously in the past few years,
which has made WES also a suitable tool to test patients
for metabolic genetic disorders with a more defined clinical
spectrum and smaller number of candidate genes, including
peroxisomal disorders, fatty acid oxidation disorders, and
many more (Lines et al. 2014; Haack et al. 2015).
The reduction in costs, the relatively simple sample collec-
tion procedure, and the broad genetic screening potential of
WES are the main reasons for the current trend of applying
WES at earlier stages of the diagnostic work-up of patients
than before. In cases where this approach results in the iden-
tification of a clear genetic defect, e.g., a known pathogenic
mutation in a disease gene associated with a phenotype that is
the same as that of the patient under investigation, the benefits
of such an Bexome-first^ approach are obvious. However, in
spite of the tremendous progress that has been made in the
development of both sequencing technology and bioinformat-
ics in recent years, it should be noted that in the majority of
investigations, whole exome (or genome) sequencing does
not result in a genetic diagnosis (Neveling et al. 2013), and
in those cases other diagnostic tests are still necessary to con-
firm or reject a diagnosis with certainty. In this paper, the
problem of genetic variants of unknown clinical significance
is explained, focusing on the field of IEM, and an overview is
given of strategies and methods to study these genetic variants
in order to understand the functional consequences of genetic
variants (Bfunctional genomics^). At the level of the individ-
ual patient, the functional data may provide key evidence to
change a possible diagnosis into a certain diagnosis. These
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functional studies can consist of specific tests to investigate a
certain genetic variant of unknown clinical significance iden-
tified in an individual patient or family. In addition, this paper
also describes some examples of prospective studies in which
functional data is collected to generate sequence-function
maps of genes. Such data can serve as reference data for the
interpretation of genetic variants that will be identified in mo-
lecular diagnostics tests in the future. Both approaches will
ultimately lead to an understanding of the function of the
entire genome and its variants.
Outcomes of WES/WGS
There are different approaches to WES data analysis. For
several reasons, in Nijmegen we have adopted a two step
approach. In step 1, the WES data is filtered using a virtual
gene panel of clinically relevant genes based on the clinical
phenotype of the patient under investigation (Neveling et al.
2013). This minimizes the chance of unsolicited findings, and
focuses the data analysis on relevant candidate genes only,
which increases the chance of identifying disease causing
variants in the WES data. If negative, an optional second step
is an exome-wide investigation of the WES data outside the
virtual gene panel (or panels) investigated in step 1. The
success of WES depends not only on the technical quality
of the sequencing data, but also on the amount of clinical-
and other patient-derived data that is available. The more
specific clinical information is known, the better the quality
of the interpretation of the WES data, and the smaller the
chance of unsolicited genetic findings. For this reason, sever-
al tools have been developed to combine exome sequencing
data with clinical data, such as eXtasy, Exomizer, PhenoVar,
Phen-Gen, and Phevor (Sifrim et al. 2013; Javed et al. 2014;
Robinson et al. 2014; Singleton et al. 2014; Trakadis et al.
2014). There are several possible outcomes of a WES or
whole genome sequencing (WGS) approach (Fig. 1): 1) de-
tection of a known disease causing variant in a disease gene
associated with a clinical phenotype that is the same as that of
the patient under investigation, 2) detection of an unknown
variant in a known disease gene with a matching clinical
phenotype, 3) detection of a known variant in a known dis-
ease gene with a non-matching phenotype, 4) detection of an
unknown variant in a known disease gene with a non-
matching phenotype, 5) detection of an unknown variant in
a gene not previously associated with disease, and 6) no ge-
netic variant detected that could explain the phenotype of the
patient. There are several other possible outcomes, but those
described above are the most frequently encountered results,
in our experience. Strictly speaking, only in the case of the
first outcome, a genetic diagnosis has been reached with cer-
tainty. In the second outcome, if the allele frequency in the
normal population is very low to zero, and the variant results
in a change of a splice site or a missense mutation at a highly
conserved position in the gene, or a stop- or frame shift mu-
tation in genes in which such null-mutations have been
shown to be pathogenic, in most cases the result will be
considered a conclusive diagnosis. Although one should be
careful in the case such a diagnosis is partially based on
computational pathogenicity predictions. In the third, fourth,
and fifth outcome described above, a certain diagnosis has
not (yet) been reached. For the evaluation of variants in sce-
narios 2–5, there are several additional genetic factors that
should be taken into consideration, for example segregation
data, the type of mutation (e.g., nonsense, frame shift, de
novo, and so on), prevalence data, phylogenetic data, chem-
ical properties of changed amino acids, and computational
pathogenicity predictions. This has been described in more
detail in a paper on the recommendations by the American
Fig. 1 From genetic test to functional validation. After whole exome (or
genome) sequencing, genetic variants are analyzed by bioinformatics
tools and additional genetic tests (e.g., segregation analysis, population
studies) are performed. On the basis of these data, variants are classified
as not/unlikely pathogenic (class 1/2), of unknown pathogenicity (class
3), or likely/definite pathogenic (class 4/5). For class 3 variants,
functional validation studies are a powerful tool to obtain evidence for
possible pathogenicity
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College of Medical Genetics and Genomics and the
Association for Molecular Pathology about the standards
and guidelines for interpretation of genetic variants
(Richards et al. 2015). In these guidelines, there are five
criteria regarded as strong indicators of pathogenicity of un-
known genetic variants. These are: (1) the prevalence of the
variant in affected individuals is statistically higher than in
controls, (2) a variant results in an amino acid change at the
same position as an established pathogenic variant, (3) a null
variant in a gene where loss-of-function is a known mecha-
nism of disease, (4) a de novo variant, with established pa-
ternity and maternity, (5) established functional studies show
a deleterious effect. In the case of IEM in general, de novo
mutations appear not to be the major disease causing mech-
anism. Nevertheless, there are many IEM associated genes in
which de novo mutations are a rare finding, and, more im-
portantly, in a small number of genes de novo mutations are
encountered frequently, for example ABCD1 in which muta-
tions cause X-linked adrenoleukodystrophy (Wang et al.
2011), SLC25A4 causing an early-onset mitochondrial deple-
tion syndrome (Thompson et al. 2016), and SLC25A24
encoding a mitochondrial ATP-Mg/phosphate in which de
novo mutations cause a progeroid disorder (Writzl et al.
2017). There are currently many computational tools that
can be used to predict the effect of genetic variants on the
gene/protein function (Cooper and Shendure 2011). Many of
these tools, however, have not been designed to be used as a
tool to predict pathogenicity in a clinical setting. Moreover,
for some of these tools, especially those that combine several
individual tools, the training dataset of genetic variants over-
laps with the data that were used to evaluate the effectiveness
of the tools, potentially causing a bias toward certain predic-
tions (Grimm et al. 2015). For these and other reasons, the
output that these computational tools provide should be
interpreted cautiously, and should not be regarded as definite
proof of pathogenicity. Another factor that is important to
note is that in spite of uniform guidelines for the assessment
of genetic variants, significant interlaboratory differences in
variant interpretation have been observed, especially in the
interpretation of Blikely benign^ and Blikely pathogenic^ var-
iants (Amendola et al. 2016). For all the reasons mentioned
above, and coming back to the criteria described by Richards
et al., in many cases functional tests are the only option to
obtain conclusive evidence for pathogenicity of variants iden-
tified in patients. In some cases, functional data of genetic
variants may already be available, for example in databases
with prospectively collected functional data of artificially cre-
ated gene variants. In many cases, this information will not be
available, and further investigations of the genetic variant in
the patient are necessary. There are different approaches to
perform such functional validation studies, and the most fre-
quently applied ones in the field of IEM are described below
and in Fig. 2.
Evidence of pathogenicity based on omics
strategies/biomarker studies
Holistic screening approaches can be powerful, broadly appli-
cable tools to obtain additional evidence for pathogenicity of
genetic variants. Recently, it has been demonstrated in two
independent studies that mRNA expression analysis by
RNA-seq can provide important data for pathogenicity of ge-
netic variants that result in changes in mRNA expression
levels, e.g., variants causing alternative splice events or caus-
ing loss of expression of alleles (Cummings et al. 2017;
Kremer et al. 2017). In the study by Kremer et al., combining
the results of mRNA expression profile analysis in mitochon-
drial disease patient fibroblasts with WES increased the diag-
nostic yield of WES by 10%, in comparison to WES only. In
the study by Cummings et al., muscle RNA expression pro-
files of a patient cohort consisting of primary muscle disorders
were analyzed, resulting in a 35% success rate. Whether such
a high percentage can also be established for mitochondrial
disorder or other IEM with muscle involvement remains to be
established.
For IEM, it seems likely that the combination of WES/
WGS with metabolomics can provide additional evidence
for pathogenicity of unknown variants. In theory, metabo-
lomics should be more informative than mRNA expression
profiling, as the metabolome is based on the function of the
gene products and not just on the expression of the
mRNAs. This is illustrated by the results of an early study
in which genetic data was combined with targeted metabo-
lomics data in a genome-wide association study (GWAS),
showing that metabolite profiles from sera more than dou-
bled the power of the GWAS, and identified variants in
several genes involved in lipid/fatty acid metabolism
(FADS1, LIPC, ACADS, ACADM) (Gieger et al. 2008). In
a large study of nearly 8000 individuals, a similar GWAS
approach combining genetic and untargeted metabolomics
data resulted in the identification of 145 genetic loci asso-
ciated with more than 400 plasma metabolites (Shin et al.
2014). In a more recent study, WGS combined with
targeted metabolomics identified 101 genetic loci that were
associated with plasma levels of 246 metabolites, including
variants in 13 genes that are associated with IEM and other
genetic disorders (Long et al. 2017). However, there are
only a few studies in which WES/WGS and untargeted
metabolomics have been combined to diagnose IEM. One
of these is a study in which untargeted metabolomics was
performed on plasma and urine of a patient with severe
developmental delay and skeletal dysplasia. This led to
the identification of elevated levels of N-acetyl-D-
mannosamine in plasma and urine of a patient, which is
the substrate for N-acetylneuraminic acid synthase, also
known as sialic acid synthase (van Karnebeek et al.
2016). Exome sequencing performed in this patient
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revealed variants in NANS. This illustrates how metabolo-
mics can be used as a functional complement of genetic
data collected by WES to diagnose IEM patients.
Protein expression studies have already proven their value
to demonstrate pathogenicity of genetic variants in numerous
cases. Usually, protein expression analysis is performed by a
simple Western blot in order to demonstrate that genetic var-
iants result in loss of expression of the corresponding protein.
However, there are only a few examples of untargeted pro-
teomics studies for the purpose of validating genetic variants.
A recent example is a study on defects in TMEM126B, a
gene encoding an assembly chaperone of the mitochondrial
respiratory chain complex I (Heide et al. 2012). In two si-
multaneously published papers describing the identification
of mutations in TMEM126B in patients with mitochondrial
respiratory chain enzyme complex I deficiency, untargeted
protein complexome profiling was used to functionally vali-
date the genetic variants. Complexome profiling is a tech-
nique by which native protein complexes are separated by
blue native gel electrophoresis, followed by mass
spectrometric analysis of tryptic peptides derived from the
proteins in the separated protein complexes. By protein cor-
relation profiling of the data, this approach provides detailed
information about the composition of protein complexes
(Wessels et al. 2009). In the two studies on TMEM126B
mutations, complexome profiling demonstrated that the var-
iants in TMEM126B cause a specific defect in the assembly
of the mitochondrial multi-subunit enzyme complex I
(Alston et al. 2016; Sanchez-Caballero et al. 2016). These
are examples of holistic approaches, that are either untargeted
or have a broad scope, which have provided functional data
serving as evidence for the pathogenicity of genetic variants.
Validation of genetic variants by targeted
functional assays
In addition to the abovementioned untargeted Bomics^
approached, there are numerous ways to obtain evidence for
pathogenicity of genetic variants by more specific functional
funconal validaon
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Fig. 2 Examples of functional genomics approaches. These approaches,
or combinations thereof, are frequently used to investigate the
pathogenicity of genetic variants of unknown clinical significance. The
examples shown are described in a clockwise order starting in the top-left
corner. Rescue: introduction by lentiviral transduction of wild type
LYRM7 cDNA in fibroblasts from a patient with a defect in LYRM7
results in normalization of mitochondrial Rieske Fe-S protein (Hempel
et al. 2017). CRISPR/Cas9: Absence of thymidine hydroxylase (TH)
staining in iPSC-derived dopaminergic nerve cells from a patient with a
defect in PTPS, and normalization of TH expression after CRISPR/Cas9-
mediated correction of the PTPS gene (Ishikawa et al. 2016). Biomarkers:
detail of a 1H NMR spectrum of a CSF sample from a NANS patient,
showing the presence of alpha and beta forms of N-acetylmannosamine
(van Karnebeek et al. 2016). iPSC: Abnormal sarcomere organization in
iPSC-cardiomyocytes derived from fibroblasts from a Barth-syndrome
patient (BTH) with mutations in the tafazzin gene (TAZ), and
normalization of sarcomeres after transfection with TAZ-mRNA (Wang
et al. 2014). Micro-organism model: Restoration of growth on a non-
fermentable carbon source (YPG) of a mitochondrial malate
dehydrogenase-deficient yeast strain (mdh1Δ) by transfection with wild
type MDH1, but not with various mdh-mutants (Ait-El-Mkadem et al.
2017). Animal model: A cerebellar defect in CLPB knock-down
zebrafish embryos, as seen in Ac-tubulin stained embryos (the
cerebellum is indicated by the rectangle in the control animal)
(Wortmann et al. 2015, 2015)
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assays. For example, in the first report on mutations in the
mitochondrial glutamate/H+ transporter GC1 encoded by
SLC25A22, it was shown that glutamate oxidation in patient-
derived fibroblasts was impaired (Molinari et al. 2005). In
such experiments, there are in general two ways of establish-
ing a genotype-phenotype correlation as evidence for patho-
genicity of genetic variants. The first strategy is to determine if
the wild type version of the gene in which the variant has been
identified results in a rescue of the phenotype. Usually, patient
derived cells are used in such a rescue experiment, e.g., lym-
phoblasts or skin fibroblasts. The second strategy is to test the
genetic variants in model systems. These do not necessarily
have to be patient-derived models, but can for example be cell
culture models or animal models.
Rescue experiments
Rescuing of a phenotype can be done by introducing the wild
type version of the gene of interest into a cell type, either
patient-derived cells with the genetic defect, or a knock-out/
knock down model system in which the variant gene is
overexpressed. The most important prerequisite for this ap-
proach is that the patient cells or model systems show a mea-
surable biochemical or cell biological phenotype that is
known to be dependent on the gene of interest. There are
several ways to introduce DNA into cells. The selection of
the most suitable technique depends amongst others on the
cell type and on the functional read-out. For assays in which
single cells are tested, e.g., microscopy-based assays, a tran-
sient transfection procedure can be applied. For this purpose,
the gene, usually a cDNA cloned into a suitable expression
vector, is introduced into cells by using an agent or a device
that facilitates the uptake of DNA by the cells. One of the
oldest methods of transfecting cultured cells is by a calcium-
phosphate co-precipitation technique (Graham and van der Eb
1973). Nowadays, there are other, more efficient ways to in-
troduce DNA into cells transiently, for example methods that
make use of cationic lipids or by means of electroporation
(Neumann et al. 1982; Felgner et al. 1987). The efficiency
of these relatively simple and quick transient transfection pro-
cedures is often (well) below 100% and is very much cell type
dependent, making it potentially less suitable for subsequent
measurements in cell populations, e.g., enzyme measurements
in transiently transfected cell cultures, as the transfected cells
are diluted by non-transfected cells in the same cell culture.
However, for assays in which individual cells are examined,
such asmicroscopic assays, it can be a very suitable technique.
This has for example been demonstrated for Zellweger-
spectrum disorders, where transfection by electroporation of
patient-derived cultured fibroblasts with a combination of a
wild type peroxisomal gene combined with a peroxisomally
targeted green fluorescence protein (GFP) was performed.
Rescue of the phenotype was scored by microscopic exami-
nation of peroxisomal targeting of GFP in the transfected cells
(Ebberink et al. 2010).
For functional assays that require near 100% transfection
efficiency, a transient transfection procedure could be used
when followed by a cell sorting step, e.g., by including a gene
encoding green fluorescent protein in the transfection proce-
dure and sort fluorescent cells by FACS. Another more fre-
quently used approach is to use viral vectors in combination
with antibiotics resistance markers, that make it possible to
reach a 100% transduction efficiency. A lentiviral transduc-
tion system is often used for this purpose, as it is safe and
allows for efficient transduction of almost all cell types, in-
cluding non-dividing primary cells (Naldini et al. 1996).
Lentiviral transduction of patient-derived fibroblasts is a
powerful procedure to prove that a functional defect in
patient-derived cells can be rescued by the wild type version
of a cDNA of the gene of interest, provided that the cells
show a functional/biochemical defect. In the case of mito-
chondrial disorders, such a defect could be a deficiency of
one or more respiratory chain enzymes, which can be mea-
sured by spectrophotometric methods (Rodenburg 2011).
Alternatively, respirometry has been used as a more broadly
applicable read-out for lentiviral complementation of mito-
chondrial defects (Kremer and Prokisch 2017), although it
is less sensitive and less specific than individual respiratory
chain enzyme measurements. Lentiviral transduction of pa-
tient fibroblasts has been described in studies of all oxidative
phosphorylation complexes, as illustrated by these recent ex-
amples that include complex I: NDUFA9 (Baertling et al.
2017), complex II: SDHA (Renkema et al. 2015), complex
III: LYRM7 (Hempel et al. 2017), complex IV: PET117
(Renkema et al. 2017), and complex V: ATP5A1
(Jonckheere et al. 2013). Also for combined enzyme deficien-
cies, e.g., caused by defects in mitochondrial translation,
lentiviral transduction has been shown to be of value in func-
tional genetics studies, for example TRMT10C (Metodiev
et al. 2016), TSFM (Emperador et al. 2016), and PNPT1
(Alodaib et al. 2016). These are just a few of many examples
that have been published in the field of mitochondrial disor-
ders in recent years. Lentiviral transduction experiments have
also been applied to other IEM. An example of this is the
investigation of fibroblasts from patients with 2-aminoadipic
2-oxoadipic aciduria, caused by mutations in DHTKD1, that
were shown to accumulate 2-oxoadipate. This could be nor-
malized by expression of wild type DHTKD1 cDNA in these
patient-derived cells (Danhauser et al. 2012). It is important
to note that there are also pitfalls to the use of genetic com-
plementation experiments. After transduction, the expression
of the cDNA is under the control of the transcriptional regu-
latory elements present in the lentiviral vector, which may
lead to different expression levels in comparison to the en-
dogenous wild type gene of interest in control cells. As
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patient cells can in some cases also be growth-compromised
because of the genetic defect, this may result in accelerated
cell death of transduced cells (Wanschers et al. 2014). In
addition, in cases in which the mutant gene is still expressed,
there could be a competition between the endogenous and
exogenous gene product, which may result in unexpected
results. Therefore, it is important to include proper control
experiments when doing lentiviral transduction studies.
These controls should include a negative control for the trans-
duction procedure. An option could be to include a transduc-
tion of the mutated cDNA in patient-derived cells as an ad-
ditional negative control. However, as many mutant alleles
are expressed at reduced levels in patient cells, the possibility
that exogenously overexpressed mutant alleles may result in
artifacts should be taken into account. Therefore, one should
be very careful with the interpretation of the results of these
mutant allele expression studies, as also explained further
below.
Transgenic expression in model systems
As an alternative to the rescue experiments described above,
expression studies of genes containing variants of unknown
clinical significance in a model system, followed by suitable
functional assays, is often performed to investigate the func-
tional consequences of genetic variants. Such experiments
can provide strong evidence for a specific genetic variant to
impair the function of the encoded protein. Whether or not
this could be a suitable approach should be considered care-
fully, especially in the case the variant protein is not
expressed in the patient. Often, pathogenic mutations result
in reduced protein expression levels, also in the case of mis-
sense variants. This could for example be due to reduced
stability of such a variant protein. The question is what would
happen if such a variant protein, that is no longer expressed in
the patient, is tested by overexpression studies in a model
system. Usually, overexpression experiments include a test
for the expression of the mutant protein, before functional
studies are performed. However, in the case of a mutation
that only affects protein stability but not its function, it is
likely that there may be detectable protein levels in such an
overexpression study design. This protein, when expressed,
could show a considerable residual activity in the functional
assay, which may lead to the wrong conclusion that the var-
iant is not pathogenic. Therefore, in cases where it has been
shown that the variant protein is no longer expressed in pa-
tient tissue samples or in patient-derived cells, one should be
very careful with drawing conclusions from studies in which
variant proteins are overexpressed. On the other hand, in the
case the mutant protein has been shown to still be expressed
in the patient, functional studies of the variant protein does
provide very specific information about the functional
consequences of the mutation. Expression studies can be per-
formed in many different model systems, for example
zebrafish, mouse, Drosophila, yeast, or E. coli. Some fre-
quently used examples are discussed below.
Yeast
One of the organisms that is frequently used in functional
genetics studies is baker’s yeast (S. cerevisiae). It is easy to
grow and to genetically manipulate, and genetic knock outs of
virtually every yeast gene are readily available. However,
yeast can be used for functional analysis of genetic variants
in only a subset of human genes. It has been estimated that
around 25% of the known human disease genes have an an-
notated yeast ortholog, and an additional 20% have a yeast
paralog (Yang et al. 2017). In addition, not all human gene
functions can be tested in yeast, in particular the functions that
are specific for higher order organisms. Nevertheless, it is a
widely used model organism in functional genetics studies,
and some examples of its successful application to IEM are
given below. Yeast studies in the field of mitochondrial genet-
ics have a long history (Tzagoloff and Myers 1986).
Mitochondrial yeast studies often make use of the fact that
respiration deficient strains show poor growth on non-
fermentable carbon sources, such as ethanol or glycerol,
whereas growth on fermentable carbon sources (e.g., glucose)
is normal. The first yeast genes responsible for this phenotype
were identified in the early 1960s (Sherman 1963). In a more
recent study in which a genome-wide screen was performed to
identify genes involved in mitochondrial respiration, more
than 10,000 gene deletion strains were tested for differential
growth on fermentable and non-fermentable carbon sources.
This resulted in the identification of 466 genes essential for
respiration (Steinmetz et al. 2002). The human orthologs of
many of those genes are now known to be associated with
mitochondrial disease. One of the genes identified in the study
by Steinmetz et al. as essential for respiration is MDH2 (in
yeast calledMDH1), encoding mitochondrial malate dehydro-
genase. This gene was recently identified as a mitochondrial
disease gene (Ait-El-Mkadem et al. 2017). In this study, mu-
tations identified in patients were functionally validated by
making use of a yeast mdh1Δ strain. The results showed that
humanMDH2 carrying the patients mutations failed to rescue
growth of the mdh1Δ strain on a non-fermentable carbon
source, whereas the wild type human MDH2 cDNA did re-
store growth of this yeast strain. In addition to mitochondrial
disorders, yeast has been used for the functional studies of
many other IEMs. One of the earliest examples of this was a
study in which a genetic variant in GALT encoding galactose-
1-phosphate uridyltransferase was investigated. While a
cDNA encoding human GALTwas able to restore the growth
on galactose-containing medium of a yeast GAL7 (the yeast
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ortholog of human GALT) knock out strain, a GALT cDNA
with the patients mutation was unable to do so, demonstrating
that the amino acid substitution disrupts GALT function
(Fridovich-Keil and Jinks-Robertson 1993).
Zebrafish
A vertebrate model system that is frequently used to test ge-
netic variants is the zebrafish. This animal is very suitable to
study (amongst others) developmental abnormalities, as for
example illustrated by a recent study of classic galactosemia
in a zebrafish model showing reduced motor activity and im-
paired fertility (Vanoevelen et al. 2017). Zebrafish embryos
can be genetically manipulated by different techniques. There
is a large number of mutant alleles available for further inves-
tigations (Kettleborough et al. 2013). One of the most fre-
quently used approaches is the injection of zebrafish embryos
with specific morpholinos that block the expression of the
gene of interest, after which a capped mRNA carrying the
mutation (or wild type mRNA as control) can be injected
and the phenotype of the developing fish can be monitored.
An example of a successful application of this approach is a
study in which the effects on mutations in CLPB on the de-
veloping central nervous system were studied to validate the
functional consequences of genetic variants in this gene
(Wortmann et al. 2015, 2015). CLPB encodes a mitochondrial
molecular chaperone and is a member of the AAA+ superfam-
ily of ATPases. It is an ATP-dependent disaggregase that sol-
ubilizes protein aggregates, and is essential for cell survival
during severe stress (Doyle and Wickner 2009). Patients with
mutations in this gene show cataracts, neutropenia, and 3-
methylglutaconic aciduria, as well as a broad spectrum of
neurological involvement with, in the most severe cases, an
almost complete absence of neurological development
(Pronicka et al. 2017). In the study in which mutations in this
gene were described for the first time, all patients showed a
neurological phenotype ranging from intellectual disability to
congenital encephalopathy with progressive brain atrophy
(Wortmann et al. 2015, 2015). In the zebrafish model, injec-
tion of CLPB morpholinos induced clear signs of cerebellar
abnormalities that could be rescued bywild type humanCLPB
mRNA but not by CLPB mRNAs carrying the patient muta-
tions, demonstrating a causal relationship between the neuro-
logical phenotype and the CLPBmutations. Another example
is the study of a genetic variant in DGAT2 (encoding diacyl-
glycerol acyltransferase 2), that had been identified by exome
sequencing in a family with autosomal dominant Charcot-
Marie-Tooth disease. In this study, it was shown that the mis-
sense variant inhibited the axonal branching in peripheral neu-
rons of the developing zebrafish, providing important evi-
dence for pathogenicity of the DGAT2 genetic variant as a
cause for Charcot-Marie-Tooth disease type 2 neuropathy
(Hong et al. 2016). Both studies illustrate that, in spite of a
lack of a specific functional assay, the use of the zebrafish
model systemmade it possible to demonstrate the pathogenic-
ity of individual genetic variants in the two genes that were
studied. In addition to these examples of studies using the
zebrafish model that were initiated on the basis of genetic
findings in patients, it has been suggested to develop the mod-
el into a medium to high through put system to study genes on
a larger scale (Davis et al. 2014), and some steps in this direc-
tion have indeed been made (Varshney et al. 2016).
iPSC
Many disease genes are expressed in a tissue specific manner
and encode proteins that have tissue-specific functions, which
may be difficult to study in cultured patient-derived cells, e.g.,
lymphoblasts or fibroblasts, or in model systems, e.g., yeast.
Around ten years ago, it was discovered that somatic cells can
be reprogrammed into pluripotent stem cells (iPSCs)
(Takahashi and Yamanaka 2006). These iPSCs can be differ-
entiated in a variety of cell types, for example neurons or
cardiomyocytes. This has opened up new possibilities to study
genetic variants in patient-derived differentiated cells in cell
culture (Park et al. 2008; Onder and Daley 2012). When creat-
ing iPSCs from patient-derived somatic cells, such as fibro-
blasts, there is a possibility that the genotype of the patient
may affect both the generation of iPSCs as well as the differ-
entiation process of iPSCs (Gibson and Thakkar 2017). For
mitochondrial disorders, it has been shown for iPSCs generated
from fibroblasts of patients with Leber’s hereditary optic neu-
ropathy (LHON) caused by mtDNA mutations that neither the
reprogramming process nor the pluripotency of the generated
iPSCs, as determined by a teratoma formation test, were altered
(Hung et al. 2016). By contrast, another study has shown that
the mtDNA mutation load in iPSCs derived from the so-called
mutator mouse, with a proofreading defect in the mtDNA po-
lymerase γ, does affect the differentiation potential of iPSCs
(Wahlestedt et al. 2014). Furthermore, inhibition of mitochon-
drial energy metabolism by rotenone or oligomycin, as well as
genetic disruption of the mitochondrial transcription factor
Tfam, has been shown to interfere with the differentiation of
iPSCs into the neurogenic lineage (Beckervordersandforth
et al. 2017). Such effects on iPSCs formation and differentia-
tion may therefore be gene-dependent, or even mutation-de-
pendent. In spite of these issues, iPSCs have been successfully
used as a tool in functional genomics studies. In a recent study
of coenzyme Q10 deficiency caused by a mutation in COQ4,
iPSCs were generated from patient fibroblasts (Romero-Moya
et al. 2017). The differentiation of the iPSCs into both dopami-
nergic and motor neurons was shown to be unaltered in com-
parison to control iPSCs. The patient-derived iPSCs showed
clear signs of mitochondrial abnormalities caused by the
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coenzyme Q10 deficiency. Interestingly, the authors restored
the genetic defect by gene editing of the COQ4 gene by using
CRISPR/Cas9, which normalized the biochemical phenotype
of the iPSCs. This provided important proof of the pathogenic-
ity of theCOQ4 genetic defect, illustrating the use of both iPSC
technology and CRISPR/Cas9 gene editing as tools for the
functional validation of genetic defects. Another example in
which iPSC technology was successfully applied to investigate
the functional consequences of mutations was a study in which
iPSC-derived cardiomyocytes of a Barth syndrome patient
with a defect in TAZ were investigated. The cardiomyocytes
showed various functional defects, including irregular sarco-
meres, weak contractility, reduced cardiolipin content, and re-
duced maximal respiration, reproducing some of the cardiac
features seen in Barth syndrome patients (Wang et al. 2014).
The authors used the iPSC-cardiomyocyte model to test vari-
ous compounds for potential therapeutic effects, and showed
that linoleic acid partially corrected the phenotype of these
cells. This study illustrates that iPSCs are not only a useful tool
in functional genomics studies, but also can serve as a model
system for experiments on therapeutic interventions.
Databases with functional information
There are several genetic variation databases providing allele
frequency about genetic variants (e.g. , gnomAD
(gnomad.broadinstitute.org), Exome Variant Server (evs.gs.
washington.edu/EVS), 1000 Genomes Browser (www.ncbi.
nlm.nih.gov/variation/tools/1000genomes), the Leiden Open
Variation Database (LOVD; www.lovd.nl), ClinVar (www.
ncbi.nlm.nih.gov/clinvar), ClinGen (www.clinicalgenome.
org)). The availability of shared genetic data in such
databases, as well as the possibility to share information by
match-making tools such as GeneMatcher that make it possi-
ble to find patients with the same rare condition (Sobreira et al.
2015), are extremely important in the day-to-day practice of
clinical genetics. However, there are no such easily accessible
and comprehensive databases with functional data of genetic
variants (yet). Nevertheless, there are many publically acces-
sible databases containing a wealth of information on gene/
protein function that could be helpful in the interpretation of
genetic variants. Examples of these are the Kyoto encyclope-
dia of genes and genomes (KEGG; www.genome.jp/kegg)
with information on all cellular functions, including
metabolic pathways; Brenda (www.brenda-enzymes.info)
with information on enzyme function; and GeneCards
(www.genecards.org), with information on all human genes,
including links to various other databases. There are also
several databases for which a subscription fee is required,
for example the Online Metabolic and Molecular Bases of
Inherited Disease (ommbid.mhmedical.com). In addition to
these general reference databases, there are databases with
functional information generated by knock-down or knock-
out of entire genes, which does give information on the pos-
sible involvement of certain genes in certain pathways. There
have been several studies in which genome-wide gene knock-
outs (or knock downs) have been performed to obtain func-
tional information, and these data could be of help for the
interpretation of WES data. A recent example of this is the
study in which a genome-wide CRISPR/Cas9 knock-out
screen was performed to identify genes essential for the mito-
chondrial oxidative phosphorylation system (Arroyo et al.
2016). In this screen, a genome-wide CRISPR single guide
RNA (sgRNA) library was transfected into human embryonic
kidney cells (HEK293) grown on a glucose-containing cell
culture medium, after which a positive selection of transfected
cells was performed to remove non-transfected cells. After
several days of growth, the culture medium was replaced by
galactose-containing medium. Cells that lack a properly func-
tioning OXPHOS do not survive in this medium. The dying
cells were harvested by using Annexin V-microbeads, after
which the sgRNAs from these dying cells were amplified
and sequenced. In this way, 191 genes were identified as es-
sential for OXPHOS, including 72 known disease genes. It
should be noted, however, that the screen picked up only a
subset of the known OXPHOS genes. This means it is likely
that there are many more genes than the 191 identified as
essential for OXPHOS in this model system. Nevertheless,
the list could in certain cases be informative when interpreting
genetic variants identified by WES. As this list is based on
functional data, it provides more convincing evidence for a
role in mitochondrial OXPHOS than the lists of genes with
predicted and partially validated subcellular mitochondrial lo-
calization of gene products, such as MitoCarta (Calvo et al.
2016) and Mitominer (Smith and Robinson 2016). However,
with respect to the use of such gene lists inWES data filtering,
the latter two lists are still very useful as they provide much
more comprehensive lists of genes (putatively) involved in
mitochondrial functions. There are several other examples of
more detailed, prospective functional testing of genetic vari-
ants, yielding functional information that could be used in the
interpretation of genetic test results. One of the earliest exam-
ples of this was a so-called alanine-scan, in which a total of 62
amino acids in three important domains of the hGH-receptor
were functionally tested, revealing that at least 12 of the res-
idues are important for hGH-receptor binding (Cunningham
and Wells 1989). A more recent example is a study in which
more than 600,000 variants introduced in the WW-domain,
which is a conserved protein-protein interaction module that
is present in many different proteins, were functionally tested
for binding by using a phage-display procedure (Fowler et al.
2010). The variants were selected over multiple rounds for
binding to peptide coated-beads, and the filtered variants were
sequenced, producing a sequence-function map for the WW-
domain. More recently, a study was performed in which all
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possible missence variants in PPARGwere functionally tested,
by expressing a cDNA library with the variants in macro-
phages lacking endogenous PPARγ, followed by exposure
to PPARγ ligand and FACS screening for CD36 expression,
which is a target for PPARγ (Majithia et al. 2016). The cDNA
sequences in both the CD36+ and CD36- populations were
sequenced, and function scores were generated for the differ-
ent amino acid substitutions. Another very recent example is
based on the concept described by Fowler et al., as mentioned
above, in which functional maps of missense variants in six
human genes (including TPK1 encoding thiamin
pyrophosphokinase) were produced by performing functional
tests of variants in a yeast model system in combination with
machine learning to refine the functional map of these genes
(Weile et al. 2017). Although there are also limitations of these
approaches (for example, the availability of a yeast screen)
and questions about factors of which the functional conse-
quences may be difficult to test in an overexpression model
system (for example mild effects on protein stability), there is
enormous potential in such large scale, prospective studies of
all known genetic variants, to produce reference databases that
could be very helpful in the interpretation of genetic variants
detected in patients (Starita et al. 2017).
Diagnostics or research
When encountering variants in novel disease genes, it is usu-
ally possible to obtain functional evidence for pathogenicity
through scientific research collaborations, as the results are
not only of diagnostic importance, but are also likely to have
a scientific impact. However, when investigating unknown
variants in known disease genes, the scientific impact of find-
ings may not be as high as in the case of novel disease genes.
Nevertheless, for the patient and family members it is very
important to obtain convincing evidence of pathogenicity, also
in the case of variants in genes that may be less interesting
from a scientific point of view. For this reason it is important
to implement functional genomics tests in a diagnostic setting.
In such a diagnostic setting, the costs and turnaround time of
such tests are important issues to take into consideration. In
addition, expectations about the possible outcomes of func-
tional tests should be managed by providing information
about chances of false positive or false negative test results.
For these and other reasons, it is as yet unclear if all of the
abovementioned approaches are suitable to be implemented in
a diagnostic setting. Acceptable costs and turnaround times
are more likely to be achieved when the number of tests
reaches sufficient volumes, which is also of importance for
maintaining a high quality level and for implementation of
proper diagnostic quality control checks. Possibilities to create
this are to develop functional assays that are broadly applica-
ble, such as metabolic flux analysis. A higher level of specific
functional testing in a diagnostic environment may be achiev-
able when diagnostic centers/functional genomics laboratories
focus on specific (groups of) disorders or types of functional
tests, and make it possible that other centers can send in diag-
nostic requests for functional validation studies. Such special-
ization will also be beneficial for selecting the most optimal
approach for functional follow-up of genetic test results.
Many types of functional tests depend on the availability of
patient material, such as skin fibroblasts or EBV-transformed
lymphoblasts, and therefore it is of importance to take the
possibility of collecting patient material into consideration
when initiating WES/WGS diagnostics.
In conclusion, the introduction ofmassive parallel sequenc-
ing in diagnostic molecular genetics has revolutionized the
field of IEM. It has made it possible to identify even the rarest
of genetic defects by a routinely performed diagnostic test,
such as whole exome sequencing. It has also created new
diagnostic challenges because of the detection of increasing
numbers of genetic variants of unknown clinical significance.
Currently, exome sequencing is operational as a diagnostic
test in many genetic centers. The next major step is already
taking place, with the introduction of whole genome sequenc-
ing in a diagnostic laboratory environment. This will lead to
growing numbers of even more challenging questions about
the possible functional consequences of unknown genetic var-
iants. Functional tests are a powerful way to demonstrate the
pathogenicity of such genetic variants, and therefore the func-
tional genomics laboratory will be an important complement
to genetics laboratories in the years to come.
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